(MNPR) Monopar Therapeutics - Ratings and Ratios

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is focused on developing innovative therapeutics for cancer treatment. The companys pipeline includes several promising candidates, including ALXN1840, a once-daily oral medicine, and MNPR-101, a humanized monoclonal antibody targeting urokinase plasminogen activator receptor (uPAR) in advanced solid tumors. MNPR-101 is being conjugated with various radioisotopes to create both diagnostic and therapeutic agents, such as MNPR-101-Zr for imaging and MNPR-101-Lu for radiotherapeutics. The company has established collaborations, notably with NorthStar, to develop radio-immuno-therapeutics, initially targeting severe COVID-19.

With a strong foundation in research and development, Monopar Therapeutics has positioned itself in the competitive biotech landscape with a unique approach to cancer treatment. The companys strategy involves leveraging its proprietary technology to create targeted therapies that can potentially improve patient outcomes. As a result, Monopar Therapeutics has garnered attention from investors and industry experts alike, reflected in its market performance.

Analyzing the , we observe that MNPR has shown significant price movement, with a last price of $39.42 and an ATR of $4.42, indicating a volatility of 11.22%. The stock is currently above its SMA50 and SMA200, suggesting a positive trend. The 52-week high and low are $51.89 and $2.21, respectively, showcasing substantial growth potential. From a fundamental perspective, the indicates a market capitalization of $265.16M USD, with no P/E ratio due to the companys focus on R&D and lack of earnings.

Forecasting based on the available and , we can infer that MNPRs continued progress in its clinical trials and potential approval of its therapeutics could drive the stock price higher. If the SMA20 continues to decline towards the current price, it may indicate a buying opportunity. Conversely, failure to meet clinical trial endpoints or delays in approvals could negatively impact the stock. Given the current SMA trends and volatility, a potential target price could be around $50 in the near term, with a stop-loss around $35 to mitigate risk. However, this forecast is contingent upon successful execution of the companys R&D strategy and favorable market conditions.